132 related articles for article (PubMed ID: 24166603)
1. The immunohistochemical expression of CD24 and CD171 adhesion molecules in borderline ovarian tumors.
Moulla A; Miliaras D; Sioga A; Kaidoglou A; Economou L
Pol J Pathol; 2013 Oct; 64(3):180-4. PubMed ID: 24166603
[TBL] [Abstract][Full Text] [Related]
2. Adhesion molecules CD171 (L1CAM) and CD24 are expressed by primary neuroendocrine carcinomas of the skin (Merkel cell carcinomas).
Deichmann M; Kurzen H; Egner U; Altevogt P; Hartschuh W
J Cutan Pathol; 2003 Jul; 30(6):363-8. PubMed ID: 12834484
[TBL] [Abstract][Full Text] [Related]
3. L1 (CAM) (CD171) in ovarian serous neoplasms.
Daponte A; Kostopoulou E; Kollia P; Papamichali R; Vanakara P; Hadjichristodoulou C; Nakou M; Samara S; Koukoulis G; Messinis IE
Eur J Gynaecol Oncol; 2008; 29(1):26-30. PubMed ID: 18386459
[TBL] [Abstract][Full Text] [Related]
4. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors.
Choi YL; Kim SH; Shin YK; Hong YC; Lee SJ; Kang SY; Ahn G
Gynecol Oncol; 2005 May; 97(2):379-86. PubMed ID: 15863133
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors.
Palazzo JP; Monzon F; Burke M; Hyslop T; Dunton C; Barusevicius A; Capuzzi D; Kovatich AJ
Hum Pathol; 2000 Jun; 31(6):698-704. PubMed ID: 10872663
[TBL] [Abstract][Full Text] [Related]
6. Expression of p16, p53, CD24, EpCAM and calretinin in serous borderline tumors of the ovary.
Aktaş IY; Buğdayci M; Usubütün A
Turk Patoloji Derg; 2012; 28(3):220-30. PubMed ID: 23011824
[TBL] [Abstract][Full Text] [Related]
7. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
8. CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells.
Davidson B
Hum Pathol; 2016 Dec; 58():123-127. PubMed ID: 27589896
[TBL] [Abstract][Full Text] [Related]
9. Expression of neural cell adhesion molecule L1 (CD171) in neuroectodermal and other tumors: An immunohistochemical study of 5155 tumors and critical evaluation of CD171 prognostic value in gastrointestinal stromal tumors.
Inaguma S; Wang Z; Lasota JP; Miettinen MM
Oncotarget; 2016 Aug; 7(34):55276-55289. PubMed ID: 27419370
[TBL] [Abstract][Full Text] [Related]
10. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
11. CD56 (Neural Cell Adhesion Molecule) Expression in Ovarian Carcinomas: Association With High-Grade and Advanced Stage But Not With Neuroendocrine Differentiation.
Bösmüller HC; Wagner P; Pham DL; Fischer AK; Greif K; Beschorner C; Sipos B; Fend F; Staebler A
Int J Gynecol Cancer; 2017 Feb; 27(2):239-245. PubMed ID: 27984374
[TBL] [Abstract][Full Text] [Related]
12. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia.
Kalir T; Wang BY; Goldfischer M; Haber RS; Reder I; Demopoulos R; Cohen CJ; Burstein DE
Cancer; 2002 Feb; 94(4):1078-82. PubMed ID: 11920478
[TBL] [Abstract][Full Text] [Related]
14. MORPHOPHENOTYPIC CHARACTERISTICS OF OVARIAN SEROUS BORDERLINE TUMORS.
Munjishvili V; Barabadze E; Musashvili T; Gachechiladze M; Burkadze G
Georgian Med News; 2019 May; (290):20-25. PubMed ID: 31322508
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical localization of survivin in serous tumors of the ovary.
Tringler B; Lehner R; Shroyer AL; Shroyer KR
Appl Immunohistochem Mol Morphol; 2004 Mar; 12(1):40-3. PubMed ID: 15163018
[TBL] [Abstract][Full Text] [Related]
16. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
18. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
Brustmann H
Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors.
Yasunaga M; Ohishi Y; Oda Y; Misumi M; Iwasa A; Kurihara S; Nishimura I; Okuma E; Kobayashi H; Wake N; Tsuneyoshi M
Hum Pathol; 2009 Jul; 40(7):965-74. PubMed ID: 19269675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]